28 Apr 2014 07:00
SILENCE THERAPEUTICS PLC
Gene knockdown in non-human primates
28 April 2014
Silence Therapeutics is pleased to announce that it has successfully shown gene knockdown in non-human primates using its RNA lung delivery system, DACC. This confirms that Silence Therapeutics has a broad delivery capability in RNA Therapeutics with validated delivery systems in the lung and the vasculature in vitro, in rodents and in non-human primates. The company's systemic vasculature delivery system, AtuPlex, is also currently being used in human clinical trials with an excellent safety profile.
Silence's Chief Executive Officer Ali Mortazavi said:
"The translation of our rodent data in DACC to non-human primates is a significant milestone. We have a broad and diversified technology platform from which to capitalise on our promise of becoming a product company. The ability to deliver RNA payloads to multiple tissues gives us a wide variety of choice from which to build a drug pipeline."
For further information please contact:
|